N/A
N=9
Exercise Mode and Acute Bone Resorption
Osteoporosis · Aging
Bottom Line
View on ClinicalTrials.gov: NCT04815824 ↗Enrolled (actual)
9
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcome: Primary: C-telopeptide of Type I Collagen (CTX) Change — 0.09; 0.08 ng/mL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Exercise Mode (Behavioral)
- Age
- Adult, Older Adult · 60+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY C-telopeptide of Type I Collagen (CTX) Change |
0.09; 0.08 | — |
| SECONDARY Procollagen of Type I N-terminal Propeptide (P1NP) Change |
-3.1; -1.5 | — |
Summary
Endurance exercise is often recommended to improve cardiometabolic health and maintain bone health throughout life and to prevent osteoporotic fracture. However, there is evidence to suggest that bone does not always adapt in the way that is expected, and that endurance exercise may lead to bone loss under certain conditions. Disruptions in calcium homeostasis during exercise may explain this observation, and preliminary data suggests that the mode of exercise (i.e., cycling versus treadmill) may result in different magnitudes of change in bone biomarkers. The purpose of this study is to determine if mode of exercise results in a differential bone biomarker response to an acute exercise bout in older Veterans. Blood samples will be collected before, during, and after 2 acute exercise bouts: 1) brisk treadmill walking; and 2) vigorous stationary cycling. Bouts will be matched for relative intensity and duration. This data will be used to develop future exercise interventions in older Veterans aimed at preserving both cardiometabolic and bone health.
Eligibility Criteria
Inclusion Criteria
- Healthy older (60+ y) Veteran women and men will be eligible to participate
- All volunteers must be accustomed to performing 60 minutes of vigorous cycling and treadmill exercise
Exclusion Criteria
- impaired renal function, defined as an eGRF of 1.5 times the upper limit of normal
- thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH) 5.0 mU/L
- serum Ca 10.3 mg/dL; 5) serum 25(OH)D 150 mmHg or diastolic BP >90 mmHg
- history of type 1 or type 2 diabetes
- cardiovascular disease; defined as subjective or objective indicators of ischemic heart disease (e.g., angina, ST segment depression) or serious arrhythmias at rest or during the graded exercise test (GXT)
- volunteers who have a positive GXT can be re-considered after follow-up evaluation, which must include diagnostic testing (e.g., stress echocardiogram or thallium stress test) with interpretation by a cardiologist
- anemia, defined as a serum hemoglobin <12.1 g/dL for women and <14.3 g/dL for men
- fracture in the past 6 months
- current diagnosis or symptoms of COVID-19
- In the event of abnormal BP, live function, TSH, 25(OH)D, or hemoglobin values, volunteers can be reassessed, including after appropriate follow-up evaluation and treatment by a primary care provider
- Those who have experienced symptoms of COVID-19 or have been formally diagnosed will be allowed to participate once symptoms have resolved and they are approved to return to exercise by their primary care provider
Data sourced from ClinicalTrials.gov (NCT04815824). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.